NO20084810L - Rekombinant svekkede clostridium-organismer og vaksine - Google Patents

Rekombinant svekkede clostridium-organismer og vaksine

Info

Publication number
NO20084810L
NO20084810L NO20084810A NO20084810A NO20084810L NO 20084810 L NO20084810 L NO 20084810L NO 20084810 A NO20084810 A NO 20084810A NO 20084810 A NO20084810 A NO 20084810A NO 20084810 L NO20084810 L NO 20084810L
Authority
NO
Norway
Prior art keywords
organisms
alpha toxin
vaccine
attenuated
recombinant attenuated
Prior art date
Application number
NO20084810A
Other languages
English (en)
Inventor
Mark D Cochran
Gary Petersen
Steven V Lair
Richard Synenki
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of NO20084810L publication Critical patent/NO20084810L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Feed For Specific Animals (AREA)

Abstract

Sammendrag Den foreliggende oppfinnelse beskriver svekkede Clostridium perfringens-organismer som uttrykker et i det vesentlige ikke-toksisk alfatoksin. Det uttrykte alfatoksin er en delesjonsmutert form som, i forhold til alfatoksinet til det modne alfatoksinet fra Clostridium perfringens stamme 13, mangler minst 9 sammenhengende aminosyreresidier, inkludert HiS68. Den foreliggende oppfinnelse beskriver også svekkede organismer som koder for de muterte formene, så vel som anvendelse av slike svekkede organismer som vaksiner. (Fig. 1)
NO20084810A 2006-04-17 2008-11-14 Rekombinant svekkede clostridium-organismer og vaksine NO20084810L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79255306P 2006-04-17 2006-04-17
PCT/US2007/009135 WO2007123850A2 (en) 2006-04-17 2007-04-12 Recombinant attenuated clostridium organisms and vaccine

Publications (1)

Publication Number Publication Date
NO20084810L true NO20084810L (no) 2009-01-16

Family

ID=38625523

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084810A NO20084810L (no) 2006-04-17 2008-11-14 Rekombinant svekkede clostridium-organismer og vaksine

Country Status (24)

Country Link
US (3) US7732187B2 (no)
EP (2) EP2007420B1 (no)
JP (2) JP5551933B2 (no)
KR (1) KR20080110908A (no)
CN (1) CN101489584B (no)
AR (2) AR060471A1 (no)
AU (1) AU2007240949B2 (no)
BR (1) BRPI0711572A2 (no)
CA (1) CA2649426C (no)
CO (1) CO6140037A2 (no)
EC (1) ECSP088827A (no)
ES (1) ES2401810T3 (no)
HK (1) HK1125315A1 (no)
IL (1) IL194714A (no)
MX (1) MX2008013451A (no)
NO (1) NO20084810L (no)
NZ (1) NZ571970A (no)
PE (1) PE20080167A1 (no)
PL (1) PL2007420T3 (no)
RU (2) RU2445364C2 (no)
TW (1) TWI338045B (no)
UA (2) UA109105C2 (no)
WO (1) WO2007123850A2 (no)
ZA (1) ZA200808872B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8617823B2 (en) * 2008-04-29 2013-12-31 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
US20130224164A1 (en) * 2010-09-10 2013-08-29 Viropharma Incorporated Environmental Clostridial Bacteriotherapy and Related Formulations and Methods of Manufacture and Use
CN103998056B (zh) 2011-07-22 2017-09-12 诺瓦蒂格姆疗法有限公司 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
CN108101983A (zh) * 2012-03-02 2018-06-01 瑞泽恩制药公司 艰难梭状芽孢杆菌毒素的人源抗体
PL2911688T3 (pl) 2012-10-26 2020-03-31 Intervet International B.V. Szczepionki zapewniające ochronę krzyżową przeciwko salmonelli
EA030005B1 (ru) 2013-03-15 2018-06-29 Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер Композиции и способы лечения грибковых и бактериальных патогенов
JP2019507759A (ja) 2016-03-09 2019-03-22 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット
CN109602898B (zh) * 2018-12-28 2022-02-22 江苏省农业科学院 一种产气荚膜梭菌α毒素基因工程疫苗及其制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN114621963A (zh) * 2022-03-11 2022-06-14 牧原食品股份有限公司 一种猪魏氏梭菌a型的亚单位疫苗及其制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1483042A (en) * 1974-07-29 1977-08-17 Lapointe J Anti-tumour product of bacterial origin
SU627610A1 (ru) 1977-09-30 1980-02-05 Zemlyakova V P Препарат землаково в.п. против клюстридиозов животных и птиц
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
ES2185631T3 (es) * 1992-05-20 2003-05-01 Secr Defence Vacunas de clostridium perfringens.
GB9605222D0 (en) 1996-03-12 1996-05-15 Secr Defence Clostridium perfringens epsilon toxin vaccines
PT892054E (pt) * 1997-06-20 2007-02-28 Intervet Int Bv Vacina de clostridium perfringens
RU2129441C1 (ru) * 1997-12-10 1999-04-27 Пирожков Михаил Константинович Вакцина, ассоциированная против анаэробной энтеротоксемии и эшерихиоза поросят
US6399074B1 (en) * 1998-07-24 2002-06-04 Megan Health, Inc. Live attenuated salmonella vaccines to control avian pathogens
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2004052393A1 (en) * 2002-12-09 2004-06-24 University Of Georgia Research Foundation, Inc. Coccidial vaccine and methods of making and using same
EP1694359A2 (en) * 2003-11-10 2006-08-30 UAB Research Foundation Compositions for reducing bacterial carriage and cns invasion and methods of using same
MY149604A (en) 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine

Also Published As

Publication number Publication date
US7807456B2 (en) 2010-10-05
WO2007123850A3 (en) 2008-03-06
ES2401810T3 (es) 2013-04-24
BRPI0711572A2 (pt) 2011-11-16
IL194714A (en) 2015-03-31
TW200801182A (en) 2008-01-01
HK1125315A1 (en) 2009-08-07
MX2008013451A (es) 2008-10-30
JP5551933B2 (ja) 2014-07-16
TWI338045B (en) 2011-03-01
AR060471A1 (es) 2008-06-18
CA2649426A1 (en) 2007-11-01
PL2007420T3 (pl) 2013-08-30
US7972604B2 (en) 2011-07-05
WO2007123850A2 (en) 2007-11-01
US20100166800A1 (en) 2010-07-01
US20070286874A1 (en) 2007-12-13
UA95951C2 (en) 2011-09-26
JP2009533071A (ja) 2009-09-17
JP2013255518A (ja) 2013-12-26
CN101489584B (zh) 2013-05-01
US20110008389A1 (en) 2011-01-13
RU2008144913A (ru) 2010-05-27
US7732187B2 (en) 2010-06-08
UA109105C2 (uk) 2015-07-27
CO6140037A2 (es) 2010-03-19
ZA200808872B (en) 2009-11-25
EP2368571A1 (en) 2011-09-28
AR079941A2 (es) 2012-02-29
EP2007420B1 (en) 2013-03-06
CN101489584A (zh) 2009-07-22
AU2007240949A1 (en) 2007-11-01
KR20080110908A (ko) 2008-12-19
RU2011147308A (ru) 2013-05-27
PE20080167A1 (es) 2008-03-10
ECSP088827A (es) 2008-11-27
RU2593945C2 (ru) 2016-08-10
RU2445364C2 (ru) 2012-03-20
NZ571970A (en) 2012-02-24
EP2007420A2 (en) 2008-12-31
IL194714A0 (en) 2011-08-01
AU2007240949B2 (en) 2013-03-14
CA2649426C (en) 2014-04-01

Similar Documents

Publication Publication Date Title
NO20084810L (no) Rekombinant svekkede clostridium-organismer og vaksine
ES2566740T3 (es) Vacunas y agentes terapéuticos de GAS en combinación
NZ594457A (en) Compositions and methods for the delivery of oxygen
AU2019311658A8 (en) Novel hyaluronidase variants and pharmaceutical composition comprising the same
TW200738881A (en) Dengue serotype 2 attenuated strain
MY139896A (en) Improved prrs vaccines
MY144689A (en) Dengue serotype 1 attenuated strain
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
DK1968632T3 (da) Forbedret influenzavaccine
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20082265L (no) Dispergerbare tabletter som innbefatter deferasirox
ATE521627T1 (de) Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
NZ593893A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
BR0309570A (pt) Fatores camp quiméricos para vacinação contra infecção por streptococcus
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
ATE308992T1 (de) Attenuierte bakterien verwendbar als impstoffe
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
ES2670799T3 (es) Inmunógenos desintoxicados de Escherichia coli
DK1509543T3 (da) Ikke-immunundertrykkende immunogen eller vaccinesammensætning, omfattende et muteret E7-protein fra virussen HPV-16
MXPA05008774A (es) Cepas atenuadas de vibrio cholerae mejoradas en su seguridad ambiental presentadas en forma liofilizada para la vacunacion por via oral.
DE602004015418D1 (de) Rekombinantes mva und verfahren zur erzeugung davon
DK1937712T3 (da) Polynukleotid fra Haemophilus parasuis samt dets anvendelse
US20230322870A1 (en) Actinobacillus pleuropneumoniae vaccines
NO20063017L (no) Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer
Velineni et al. Comparison of specificities of serum antibody responses of horses to clinical infections caused by Streptococcus equi or zooepidemicus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application